更新于：2024-11-01

Acute gingivitis

急性牙龈炎

更新于：2024-11-01

基本信息

别名

Acute gingival inflammation、Acute gingivitis、Acute gingivitis (disorder)

+ [8]

简介-

关联

项与急性牙龈炎相关的药物

Sodium Gualenate Hydrate

薁磺酸钠

靶点-

作用机制-

在研机构

ROHTO NITTEN Co., Ltd. [+5]

原研机构

Nippon Shinyaku Co., Ltd.

在研适应症

急性结膜炎 [+13]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

日本

首次获批日期2002-03-15

Hinokitiol/Hydrocortisone Acetate/Ethyl Aminobenzoate

靶点

GR x Nav1.8

作用机制

GR激动剂 [+1]

在研机构

Showa Yakuhin Kako Co., Ltd.

原研机构

Showa Yakuhin Kako Co., Ltd.

在研适应症

急性牙龈炎 [+1]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

日本

首次获批日期1959-06-30

项与急性牙龈炎相关的临床试验

CTRI/2024/10/074597 / Not yet recruiting临床2期IIT

Effectiveness of Lodradi Pratisarana and Ksheerivriksha kashaya Gandusha in gingivitis - NIL

开始日期2027-10-10

申办/合作机构-

CTRI/2024/07/069928 / Not yet recruiting临床3期IIT

Enhancing oral hygiene retention. A randomized controlled trial on the efficacy of dynamic multimedia tools versus traditional leaflets - NIL

开始日期2024-07-15

申办/合作机构-

CTRI/2024/06/069509 / Not yet recruiting临床3期IIT

Comparison Of Gingival Trauma Induced by Aluminium Trihydroxide Air Polishing Powder With Sodium Bicarbonate Air Polishing Powder In Subjects With Plaque Induced Gingivitis: A Randomized Controlled Clinical Trial. - nil

开始日期2024-07-05

申办/合作机构-

100 项与急性牙龈炎相关的临床结果

登录后查看更多信息

100 项与急性牙龈炎相关的转化医学

登录后查看更多信息

0 项与急性牙龈炎相关的专利（医药）

登录后查看更多信息

项与急性牙龈炎相关的文献（医药）

2024-08-18·Cureus

Clinical Features, Etiopathogenesis, and Therapeutic Approaches of Acute Gingival Lesions: A Narrative Review

Review

作者: Bhagat, Shweta ; Jaiswal, Priyanka ; Kotecha, Sakshi V

A bacterial infection is typically the source of gingivitis, a non-destructive condition that produces gum inflammation. Unlike chronic lesions, which have well-defined features and a gradual onset, acute lesions are unpleasant. Usually, the first symptoms are bleeding, swollen, and red gums. If gingivitis is not treated, it can lead to periodontitis, a more serious condition where the gums separate from the teeth. It seems that gingival disease-induced inflammation is a necessary condition for the breakdown of connective tissue attachment apical to the cementoenamel junction (CEJ). This may result in damage to the bone and soft tissue that support the teeth, leading to loosening and unstable teeth, and if the infection worsens, eventual tooth loss may occur. While one of the most prevalent inflammatory diseases in humans is plaque-induced gingivitis, there are several less common but frequently very significant non-plaque-induced gingival illnesses. Maintaining regular dental hygiene can help prevent gingivitis and make it reversible. Non-plaque-induced gingival lesions might be pathologic alterations restricted to gingival tissues, but they are also frequent signs of systemic disorders. Diagnosing patients with these lesions and creating treatment regimens for them must be the aim of the therapy.

2024-07-01·Wiadomości Lekarskie

The state of systemic immunity in congenital cleft lip and palate patients with diseases of oral cavity tissues

Article

作者: Timokhina, Tetiana O. ; Melnyk, Bohdan M. ; Holubchenko, Oleh I. ; Cherkasova, Olena V.

Aim: To determine the state of dental health and the state of systemic immunity in patients in congenital cleft lip and palate patients. Materials and Methods: The dental status and immunologic tests of 74 patients age 8-18 years old with congenital cleft lip and palate was analyzed: 43 children with unilateral and 31 children with bilateral complete combined cleft lip, alveolar process, hard and soft palate. Results: Indicators of the prevalence and intensity of the caries process in patients with congenital congenital complete cleft lip, alveolar process, hard and soft palate were high, especially in children with bilateral cleft lip and palate - the decompensated course of caries was determined in 41.93% patients, with unilateral - 23.25%. Сhronic catarrhal gingivitis was the most common in both groups of patients - the average severity of gingivitis prevailed - 51.16% with congenital unilateral cleft lip and palate and 51.61% - with bilateral. Atopic cheilitis, glossitis and chronic recurrent aphthous stomatitis were common. This patients have significant changes in the cellular chain of the immune system with a deficiency of the main phenotypes of lymphocytes - CD4+ CD8+ and inflammatory bacterial changes in blood serum. Conclusions: Patients of unilateral and bilateral complete combined cleft lip, alveolar process, hard and soft palate have significant changes in the dental status and in the cellular chain of the immune system. The level of manifestation of these changes is directly proportional to the extent of localization of the pathology - unilateral or bilateral.

2024-01-01·Molecular Pain

Acute pulpitis promotes purinergic signaling to induce pain in rats via P38MAPK/NF-κB signaling pathway

Article

作者: Qi, Fang ; Zhang, Tiejun ; Hu, Jun ; Wang, Li ; Kang, Yiqun ; Chen, Yangxi

Toothache is one of the most common types of pain, but the mechanisms underlying pulpitis-induced pain remain unknown. The ionotropic purinergic receptor family (P2X) is reported to mediate nociception in the nervous system. This study aims to investigate the involvement of P2X3 in the sensitisation of the trigeminal ganglion (TG) and the inflammation caused by acute pulpitis. An acute tooth inflammation model was established by applying LPS to the pulp of SD rats. We found that the increased expression of P2X3 was induced by acute pulpitis. A selective P2X3 inhibitor (A-317491) reduced pain-like behavior in the maxillofacial region of rats and depressed the activation of neurons in the trigeminal ganglion induced by pulpitis. The upregulated MAPK signaling (p-p38, p-ERK1/2) expression in the ipsilateral TG induced by pulpitis could also be depressed by the application of the P2X3 inhibitor. Furthermore, the expression of markers of inflammatory processes, such as NF-κB, TNF-α and IL-1β, could be induced by acute pulpitis and deduced by the intraperitoneal injection of P2X3 antagonists. Our findings demonstrate that purinergic P2X3 receptor signaling in TG neurons contributes to pulpitis-induced pain in rats and that P2X3 signaling may be a potential therapeutic target for tooth pain.

项与急性牙龈炎相关的新闻（医药）

2022-11-10

·赛柏蓝

中杰药业携「重磅产品」全国招商

【点击图片申请代理】企业简介河南中杰药业有限公司，成立于1992年，总资产2亿元，占地6万平方米，其中，自动化高架仓库、研发中心、检验基地占地2万平方米，4个GMP标准化生产车间，十条中西药现代化GMP标准生产线及颗粒剂、糖浆剂、丸剂、片剂、硬胶囊制剂、合剂、口服乳剂生产检测设备，产品涵盖了六大剂型，十大类别。65个国家药品批准文号，先后承担二项国家863计划重大科技项目，三个项目列入国家“重大新药创制”专项，是集中成药、植物药、西药、原料药、大健康产品的研发、生产和销售于一体的现代化综合医药制药企业。医疗产品招商RECRUIT盐酸倍他司汀片【点击图片申请代理】通用名称：盐酸倍他司汀片4mg×12片；4mg×24片1、产品信息：【成份】本品主要成份为盐酸倍他司汀。【适应症】用于治疗梅尼埃综合症相关的眩晕，耳鸣和听力下降。【规格】4mg【包装】药用铝箔，聚氯乙烯/聚偏二氯乙烯固体药用复合硬片包装，12片/板×1板/盒；12片/板×2板/盒。【用法用量】起始剂量每次4mg，每日3次，最好随餐服用。根据年龄和症状调整剂量，每日最大剂量48mg。2、产品优势：● 国家基药、国家医保甲类产品● 通过“一致性评价”产品● 国内竞品少，国内“过评”仅两家● 治疗梅尼埃综合症指南用药3、招商目标：等级医院、基层医疗销售团队。（省代、地代）RECRUIT盐酸倍他司汀片【点击图片申请代理】通用名称：盐酸倍他司汀片8mg×12片；8mg×24片1、产品信息：【成份】本品主要成份为盐酸倍他司汀。【适应症】用于治疗梅尼埃综合症相关的眩晕，耳鸣和听力下降。【规格】8mg【包装】药用铝箔，聚氯乙烯/聚偏二氯乙烯固体药用复合硬片包装，12片/板×1板/盒；12片/板×2板/盒。【用法用量】起始剂量每次4mg，每日3次，最好随餐服用。根据年龄和症状调整剂量，每日最大剂量48mg。2、产品优势：● 国家医保甲类产品● 通过“一致性评价”产品● 国内竞品少，国内“过评”仅两家● 治疗梅尼埃综合症指南用药3、招商目标：等级医院、私立医院销售团队。（省代、地代）RECRUIT华法林钠片【点击图片申请代理】通用名称：华法林钠片2.5mg×40片；2.5mg×60片1、产品信息：【适应症】适用于需长期持续抗凝的患者：① 能防止血栓的形成及发展，用于治疗血栓栓塞性疾病；② 治疗手术后或创伤后的静脉血栓形成，并可作心肌梗死的辅助用药；③对曾有血栓栓塞病患者及有术后血栓并发症危险者，可予预防性用药。【规格】2.5mg【包装】药用铝箔／聚氯乙烯固体药用硬片包装，20片／板×2板／盒；20片／板×3板／盒。2、产品优势：● 国家基药、国家医保甲类产品● 国内厂家少，全国仅4家● 进口替代药，拥有价格优势● 全国挂网省份多3、招商目标：等级医院、基层医疗团队。（省代）业务支持1. 省代+地代模式，严格市场保护；2. 学术宣传支持，专业商务支持；3. 统一价格体系，各级代理合理分润；4. 签订年度合作协议，保证代理商权益。医疗产品联系人荆总15236629766 OTC产品招商RECRUIT齿痛消炎灵颗粒【点击图片申请代理】通用名称：齿痛消炎灵颗粒10g×4袋（无蔗糖）1、产品信息：【功能主治】疏风清热，凉血止痛。用于脾胃积热，风热上攻所致的头痛身热、口干口臭、便秘燥结、牙龈肿痛；急性齿根尖周炎、智齿冠周炎、急性牙龈（周）炎见上述证候者。【规格】每袋装10克（无蔗糖）【包装】药品包装用复合膜包装，10克/袋×4袋/盒。【用法用量】开水冲服。一次1袋，一日3次，首次加倍。2、产品优势：● 纯中药组方制剂● 疏风清热，凉血止痛● 严格控销，维护价格3、招商目标：OTC连锁药店、三终端单体药店控销团队。（省代、地代）RECRUIT齿痛消炎灵颗粒【点击图片申请代理】通用名称：齿痛消炎灵颗粒20g×4袋1、产品信息：【功能主治】疏风清热，凉血止痛。用于脾胃积热，风热上攻所致的头痛身热、口干口臭、便秘燥结、牙龈肿痛；急性齿根尖周炎、智齿冠周炎、急性牙龈（周）炎见上述证候者。【规格】每袋装20克【包装】药品包装用复合膜包装，20克/袋×4袋/盒。【用法用量】开水冲服。一次1袋，一日3次，首次加倍。2、产品优势：● 纯中药组方制剂● 独家规格● 疏风清热，凉血止痛● 严格控销，维护价格3、招商目标：OTC连锁药店、三终端单体药店控销团队。（省代、地代）业务支持1. 省代+地代模式，严格市场保护；2. 学术宣传支持，专业商务支持；3. 统一价格体系，各级代理合理分润；4. 签订年度合作协议，保证代理商权益。OTC产品联系人何经理 15036632327 OEM产品招商RECRUIT百咳静糖浆【点击图片申请代理】通用名称：百咳静糖浆90ml/瓶、150ml/瓶、180ml/瓶、200ml/瓶多个规格全国招商1、产品信息：【功能主治】清热化痰，止咳平喘。用于外感风热所致的咳嗽、咯痰；感冒，急、慢性支气管炎，百日咳见上述证候者。【规格】每1毫升相当于饮片0.92克【包装】口服液体药用聚酯瓶装，90ml/瓶；100ml/瓶；120ml/瓶；150ml/瓶；180ml/瓶；200ml/瓶。【用法用量】口服。一至二岁一次5毫升；三至五岁一次10毫升；成人一次20～25毫升，一日3次。2、产品优势：● 纯中药制剂● 止咳、化痰、平喘、消炎多效合一● 销售基础好，市场认可度高3、招商目标：全国市场专业销售团队。（单规格全国大包）业务支持1. 订单生产保障供应；2. 全国独家授权；3. 签订年度合作协议，保证代理商权益。OEM产品联系人姚总 15903633029声明：此篇文章受众仅为医药、医疗等健康产业专业伙伴，仅供医学药学专业人士使用，不针对普通消费大众。

一致性评价